4BB

4basebio is a specialist life sciences company focused on the development and manufacture of synthetic DNA and non-viral delivery systems for use in gene therapies and vaccines. The company's proprietary hpDNA™ platform produces high-purity, large-scale synthetic DNA that offers advantages over traditional plasmid DNA, including improved safety and faster production timelines. Additionally, 4basebio provides mRNA production services and has developed the Hermes™ nanoparticle platform for targeted nucleic acid delivery. Headquartered in Cambridge, UK, the company serves pharmaceutical and biotech partners globally, supporting the advancement of advanced therapy medicinal products (ATMPs). The company is listed on the London Stock Exchange's AIM market and operates facilities in both the UK and Spain.